#HRV Pharma
Explore articles tagged with HRV Pharma
Licensed in Germany, Ready for Europe
HRV Pharma's acquisition of Germany-based Phatebo GmbH provides an established entry into the European pharmaceutical market. With German pharmaceutical wholesale authorisation, good distribution practice systems and an existing global customer base, the acquisition supports HRV's expansion into finished formulations while strengthening its international presence.
Keeping Clinical Trials on Schedule
HRV Pharma's acquisition of Germany-based Phatebo expands its business into clinical trial supply and finished formulations. Phatebo provides investigational, comparator and ancillary medicines through licensed channels, with traceability of origin, batch and expiry to support reliable clinical trial operations.
A New Chapter in Europe
HRV Pharma has entered the European finished formulations market through its acquisition of Germany-based Phatebo. The move gives HRV an established pharmaceutical business with wholesale authorisation, good distribution practice systems and an existing customer base, complementing its global API portfolio.
A Foray Into European Markets
HRV Pharma is expanding into European markets through the planned acquisition of Germany-based Phatebo GmbH. The deal provides an entry into finished formulations, clinical trial supply and established pharmaceutical distribution capabilities, including a German wholesale authorisation and long-standing relationships with clinical trial sponsors.
Beyond APIs, Into Finished Formulations
HRV Pharma is expanding beyond APIs into finished formulations through its acquisition of a 100% equity stake in Germany-based Phatebo. The acquisition marks a significant step in HRV's growth, giving the company its first finished formulations business and a licensed operating presence in Germany, while opening new opportunities in the European pharmaceutical market.
Catching Risk Before It Becomes a Recall
In the pharmaceutical industry, identifying risks early can help prevent costly quality failures and recalls. PharmaClick explores how HRV Pharma's RIKO platform uses AI-driven pharmaceutical intelligence to assess chemistry risks, nitrosamine potential, supplier reliability and regulatory history before commitments are made.
Not a Capacity Problem, a Utilisation Problem
When Hari Kiran Chereddi founded HRV Pharma in 2016, he saw an opportunity to address underutilised pharmaceutical manufacturing capacity in India. In this ET Now interview, he explains HRV's asset-light model, its quality assurance systems across 53 sites, and its ambition to reach ₹1,000 crore while remaining debt free.
What Indian Pharma Is Really Buying
Sun Pharma's $11.75 billion acquisition of Organon highlights a broader shift in the Indian pharmaceutical industry. Featuring insights from industry leaders, including HRV Pharma's Hari Kiran Chereddi, BioSpectrum explores the growing importance of brand value, specialty portfolios, biosimilars and access to regulated global markets.
No Factory, ₹400 Crore Revenue: How HRV Made It Happen
How does HRV Pharma generate over ₹400 crore in revenue without owning a manufacturing plant? Discover its asset-light business model, network of 50+ US FDA and EU approved manufacturing partners, and growth to 700+ customers across 55 countries.